Indian envoy to US visits Philadelphia, discusses healthcare and education ties
The Philadelphia Mayor thanked India for supplying two million N-95 masks in 2020
Closer healthcare and education cooperation was high on the agenda of India's Ambassador to the United States Taranjit Singh Sandhu as he visited the city of Philadelphia recently.
During the visit, he interacted with some of the top pharmaceutical companies. He also had a meeting with the city mayor.
“A pleasure to start the day in Philadelphia with a meeting with Philadelphia Mayor Jim F Kenney”, Sandhu said in a tweet as he kicked off his two-day trip to the city on June 11.
During the meeting, the discussions focused on economic, healthcare and education ties and the dynamic diaspora.
From economic, healthcare and education ties to the dynamic diaspora, India values partnership with this historic city, Sandhu said in another tweet.
Kenney thanked India for supplying two million N-95 masks to Philadelphia in 2020, Sandhu said.
Sandhu also visited the Ocugen facilities and Jubilant Pharma office in Philadelphia.
Jubilant Pharma based in Yardley, Pennsylvania, is a subsidiary of Jubilant Life Sciences Limited based in Noida, Uttar Pradesh.
Jubilant Pharma has signed a non-exclusive licensing agreement with Gilead Sciences Inc for the manufacturing and distribution of Remdesivir (API) which has received an Emergency Use Authorisation by the US Food and Drug Administration (FDA) for the treatment of COVID-19 pandemic. The authorisation belongs to the injectable form of Remdesivir only.
Noting that Indian pharmaceutical companies are playing an important role in expanding public health in the US, Sandhu tweeted, “A fruitful interaction with Jubilant Pharma leadership in #Philadelphia at the new office. Their critical drugs lead the fight against the pandemic.”
Ocugen Inc, on the other hand, is a biopharmaceutical company focused on discovering, developing, and commercialising gene therapies to treat rare and underserved eye diseases and developing a vaccine to fight COVID-19.
Ocugen CEO Shankar Musunuri and other Board members briefed Sandhu that they were in discussions with the FDA, on development and commercialisation of COVAXIN in the US market.
In February, Ocugen entered into an agreement with Bharat Biotech International Limited (Bharat Biotech) for development and commercialisation of Covaxin in the US.
“The India-US healthcare partnership continues to grow! Visited Ocugen facilities in Philadelphia and met their Board members. Discussed issues relating to bringing #Covaxin into the US," Sandhu tweeted.